PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM
- PMID: 32851110
- PMCID: PMC7442274
- DOI: 10.1093/ofid/ofaa329
PrEP Nonadherence, White Coat Dosing, and HIV Risk Among a Cohort of MSM
Abstract
Among a cohort of men who have sex with men in a pre-exposure prophylaxis (PrEP) adherence trial, syphilis requiring treatment was associated with white coat dosing (increased PrEP adherence immediately preceding study visits) when compared with participants with optimal drug concentrations. The findings highlight the need for identifying and reducing barriers to PrEP adherence.
Keywords: MSM; PrEP adherence; pre-exposure prophylaxis; syphilis; white coat dosing.
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Figures
References
-
- Feinstein AR. On white-coat effects and the electronic monitoring of compliance. Arch Intern Med 1990; 150:1377–8. - PubMed
-
- Podsadecki TJ, Vrijens BC, Tousset EP, et al. . “White coat compliance” limits the reliability of therapeutic drug monitoring in HIV-1-infected patients. HIV Clin Trials 2008; 9:238–46. - PubMed
